转自：智通财经 【保诚：以约294万英镑回购约30万股】智通财经8月18日电，保诚(02378.HK)在港交所发布公告称，8 月15日在伦交所斥资约294万英镑回购股份约29.6万股，每股回购价在9.868至9.994英镑。 ...

格隆汇8月18日丨保诚(02378.HK)发布公告，2025年8月15日耗资293.95万英镑回购29.62万股。 ...

保诚(02378)发布公告，于2025年8月15日，该公司斥资293.95万英镑回购29.62万股。 ...

智通财经APP讯，保诚(02378)发布公告，于2025年8月15日，该公司斥资293.95万英镑回购29.62万股。 ...

FF305 第 2 頁 共 7 頁 v 1.3.0 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： Prudential plc 保誠有限公司* (* 僅供識別) 呈交日期： 2025年8月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02378 | 說明 | 普通股每股0.05英鎊 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已 ...

Group 1 - The core announcement is regarding the second dividend distribution of the CITIC Prudential Stable Bond Fund, which was published on August 16 [1] - The dividend distribution base date is set for August 8, with specific dividend amounts outlined for different fund classes [1] - The dividend amounts per 10 units are as follows: CITIC Prudential Stable A (0.02), CITIC Prudential Stable C (0.02), and CITIC Prudential Stable D (0.02) [1] Group 2 - The eligible shareholders for the dividend are those registered on the equity registration date of August 18, with cash dividends to be distributed on August 19 [1] - Investors opting for reinvestment will have their cash dividends converted into fund shares based on the net asset value determined on August 18, 2025 [1] - According to relevant regulations, the fund's income distributed to investors is temporarily exempt from income tax, while any bank transfer or other handling fees incurred during the dividend distribution will be borne by the investors [1]

格隆汇8月15日丨保诚(02378.HK)发布公告，2025年8月14日耗资292.5万英镑回购29.5万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： Prudential plc 保誠有限公司* (* 僅供識別) 呈交日期： 2025年8月15日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02378 | 說明 | 普通股每股0.05英鎊 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | ...

Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]

相关事件 保诚(02378.HK)8月13日耗资294万英镑回购30万股 保诚(02378.HK)：预计8月27日公布2025年上半年度 业绩 格隆汇8月14日丨保诚(02378.HK)发布公告，2025年8月13日耗资294万英镑回购30万股。 ...